

Resource Summary Report

Generated by [NIF](#) on Aug 1, 2026

Anti-Human CD19 (H1B19)-142Nd

RRID:AB_2651155

Type: Antibody

Proper Citation

(Standard BioTools Cat# 3142001, RRID:AB_2651155)

Antibody Information

URL: http://antibodyregistry.org/AB_2651155

Proper Citation: (Standard BioTools Cat# 3142001, RRID:AB_2651155)

Target Antigen: CD19

Clonality: monoclonal

Antibody Name: Anti-Human CD19 (H1B19)-142Nd

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: H1B19

Antibody ID: AB_2651155

Vendor: Standard BioTools

Catalog Number: 3142001

Alternative Catalog Numbers: 3142001B

Record Creation Time: 20260218T234403+0000

Record Last Update: 20260226T000550+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Human CD19 (H1B19)-142Nd.

No alerts have been found for Anti-Human CD19 (H1B19)-142Nd.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 36 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Momenilandi M, et al. (2024) FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice. *Cell*, 187(11), 2817.

Kaczanowska S, et al. (2024) Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. *Cancer cell*, 42(1), 35.

Ulutekin C, et al. (2024) B cell depletion attenuates CD27 signaling of T helper cells in multiple sclerosis. *Cell reports. Medicine*, 5(1), 101351.

Shinde P, et al. (2024) A multi-omics systems vaccinology resource to develop and test computational models of immunity. *Cell reports methods*, 4(3), 100731.

Sjögren T, et al. (2024) Single cell characterization of blood and expanded regulatory T cells in autoimmune polyendocrine syndrome type 1. *iScience*, 27(4), 109610.

Rachubinski AL, et al. (2024) JAK inhibition decreases the autoimmune burden in Down syndrome. *eLife*, 13.

Sponaule A, et al. (2023) Dominant CD4+ T cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV. *Cell reports. Medicine*, 4(11), 101268.

Liu H, et al. (2023) Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. *Cancer cell*, 41(4), 693.

Nuñez NG, et al. (2023) Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. *Med (New York, N.Y.)*, 4(2), 113.

Rosain J, et al. (2023) Human IRF1 governs macrophagic IFN- γ immunity to mycobacteria. *Cell*, 186(3), 621.

Hung CN, et al. (2023) AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages. *Cell reports*, 42(9), 113067.

Jeger-Madiot R, et al. (2022) Naive and memory CD4+ T cell subsets can contribute to the generation of human Tfh cells. *iScience*, 25(1), 103566.

Salomé B, et al. (2022) NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. *Cancer cell*, 40(9), 1027.

, et al. (2022) A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. *Cell*, 185(5), 916.

Henrick BM, et al. (2021) Bifidobacteria-mediated immune system imprinting early in life. *Cell*, 184(15), 3884.

Galbraith MD, et al. (2021) Seroconversion stages COVID19 into distinct pathophysiological states. *eLife*, 10.

Xie G, et al. (2021) Characterization of HIV-induced remodeling reveals differences in infection susceptibility of memory CD4+ T cell subsets in vivo. *Cell reports*, 35(4), 109038.

Sullivan KD, et al. (2021) The COVIDome Explorer researcher portal. *Cell reports*, 36(7), 109527.

Krämer B, et al. (2021) Early IFN- γ signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. *Immunity*, 54(11), 2650.

Dhariwala MO, et al. (2020) Developing Human Skin Contains Lymphocytes Demonstrating a Memory Signature. *Cell reports. Medicine*, 1(8), 100132.